A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients

• Status: Completed
• Trial end date: 2019-11-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of paliperidone palmitate over a 9-week period for participants with schizophrenia in Korea.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Paliperidone Palmitate

Criteria

Inclusion Criteria:

• Participants diagnosed with schizophrenia

• Participants prescribed with paliperidone palmitate for acute or maintenance treatment

Exclusion Criteria:

• Participants who received paliperidone palmitate for other than the approved indication